Breast cancer treatment-target treatment
Breast cancer targeting treatment is a precise treatment, where the molecular target treatment, i.e., the specific position of the tumour cell targeted, combines with a specific drug to maximize the tumour cell and to a small extent the damage to the normal cell; it has characteristics that are specific and clearly therapeutic.
Common target drugs include anti-HER-2 drugs, CDK4/6 inhibitors, PARP inhibitors, road inhibitors, immunotherapy,
It mainly targets specific targets on breast cancer cells, which are molecules that play a key role in the growth, proliferation or transfer of cancer cells.
The drugs used are specific to these targets and, like precision-guided missiles, reduce damage to normal cells while effectively killing cancer cells. For example, for Her – 2 positive breast cancer, the drugs commonly targeted are monopolistic. This drug can disrupt the performance of Her – 2 proteins and thus inhibit the growth and spread of cancer cells.
The following are the main types of breast cancer drugs:
Anti-HER-2 Category
– Tratto-Choose: A single clone anti-Her 2 antibody, the first target-oriented therapeutic drug to be used against Her-2, which can significantly increase the survival rate of Her-2-positive breast cancer patients and is commonly used in combination with chemotherapy. It also stimulates the body ‘ s own immunosuppression cells to destroy cancer cells by keeping itself attached to Her2 to prevent human skin growth factors attached to Her2 and thereby disrupting the growth of cancer cells. Clinically, it is mainly used for transmissible breast cancer overexpressed by Her-2. Monopharmaceutical treatment can be used for transferal breast cancer, which has been the subject of one or more chemotherapy programmes; it can be treated in conjunction with PVC, which does not undergo chemotherapy.
– Pato-Choose: The combined use of Pato-Choto-Choto-Cyper-Cyper-Cyper-Cyper-Cyper-Cyco-Cyco-Cyco-Cyco-Cyco-Cyco-Cyco-Cyco-Cyco-Cyco-Cyco-Cyco-Cyco-Cy-Cyco-Cyco-Cyco-Cyco-Cyco-Cyco-Cy-Cyco-Cyco-Cy-Cyco-Cy-Cyco-Cy-Cyco-Cyco-Cy-Cy-Cy-Cy-Cyco-Cy-Cyco-Cy-Cyco-Cy-Cy-Cy-Cy-Cy-Cy-Cy-Cy-Cy-Cy-Cy-Cy-Cy-Cy-Cy-Cy-Cy-Cy-Cy-Cy-Cy-Cy-Cy
– T-DM1 (Animated by Emmetros): An antibody drug that links up the cytopharmaceutical resistance to cytotoxics and is able to deliver the drug to the HeR-2 positive cancer cells with greater lethality.
Anti-vascular generation category
– Bénédération is one-sided: tumour growth is inhibited mainly by inhibiting tumour vascular production and cutting off the nutritional supply of tumours. It can be used in combination with chemotherapy for late breast cancer treatment.
